The Van Gogh-PE Trial, a Multicenter, International, Randomized, Open-Label, Assessor-Blind, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Weekly Subcutaneous SR34006 With the Combination of (LMW) Heparin and Vitamin K Antagonist (VKA) in the Treatment of Acute Symptomatic Pulmonary Embolism.

Trial Profile

The Van Gogh-PE Trial, a Multicenter, International, Randomized, Open-Label, Assessor-Blind, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Weekly Subcutaneous SR34006 With the Combination of (LMW) Heparin and Vitamin K Antagonist (VKA) in the Treatment of Acute Symptomatic Pulmonary Embolism.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 May 2009

At a glance

  • Drugs Idraparinux sodium (Primary) ; Low molecular weight heparins; Vitamin K antagonists
  • Indications Deep vein thrombosis; Pulmonary embolism
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 14 Sep 2008 Actual end date (Oct 2005) added as reported by ClinicalTrials.gov.
    • 14 Sep 2008 Actual start date (Jun 2003) added as reported by ClinicalTrials.gov.
    • 15 Sep 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top